Surveyed Neurologists in Both the United States and Europe Indicate That a Once-Daily Transdermal Formulation of Levodopa Would Earn a 30 Percent Patient Share in Parkinson's Disease

On Tuesday April 28, 2009, 8:00 am EDT
Yahoo Financial, http://finance.yahoo.com/news/Survey...1989.html?.v=1

Stalevo Will Retain Decision Resources' Gold-Standard Status Through 2017 for Parkinson's Disease, According to a New Report from Decision Resources

WALTHAM, Mass., April 28 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a once-daily transdermal formulation of levodopa would earn a 30 percent patient share in Parkinson's disease in both the United States and in Europe, according to surveyed U.S. and European neurologists.

The new report entitled Parkinson's Disease: A Transdermal Formulation of Levodopa Would Tap into a Significant Opportunity in This Mature Market also finds that surveyed neurologists identify a therapy's effect on levodopa-induced motor response complications as one of the key attributes that strongly influences their prescribing decisions in Parkinson's disease.